Your browser is no longer supported. Please, upgrade your browser.
VCEL [NASD]
Vericel Corporation
Index- P/E3318.75 EPS (ttm)0.02 Insider Own0.90% Shs Outstand45.55M Perf Week-13.12%
Market Cap2.40B Forward P/E113.95 EPS next Y0.47 Insider Trans-34.05% Shs Float44.89M Perf Month-4.27%
Income2.90M PEG- EPS next Q-0.04 Inst Own- Short Float8.55% Perf Quarter14.22%
Sales124.20M P/S19.29 EPS this Y127.70% Inst Trans5.39% Short Ratio4.16 Perf Half Y153.82%
Book/sh2.95 P/B18.00 EPS next Y429.55% ROA1.70% Target Price61.88 Perf Year258.78%
Cash/sh1.68 P/C31.61 EPS next 5Y- ROE2.50% 52W Range12.82 - 64.89 Perf YTD71.96%
Dividend- P/FCF159.76 EPS past 5Y15.60% ROI1.60% 52W High-18.18% Beta2.08
Dividend %- Quick Ratio5.10 Sales past 5Y19.40% Gross Margin67.80% 52W Low314.20% ATR3.78
Employees273 Current Ratio5.50 Sales Q/Q14.70% Oper. Margin1.90% RSI (14)41.73 Volatility6.75% 6.98%
OptionableYes Debt/Eq0.00 EPS Q/Q7.10% Profit Margin2.30% Rel Volume0.83 Prev Close56.59
ShortableYes LT Debt/Eq0.00 EarningsMay 05 BMO Payout0.00% Avg Volume923.13K Price53.10
Recom1.70 SMA20-10.08% SMA50-0.43% SMA20062.44% Volume774,279 Change-6.17%
Jan-11-21Downgrade Oppenheimer Outperform → Perform
Dec-18-20Initiated Stephens Overweight $31
Sep-17-20Initiated Truist Buy $24
Oct-09-19Initiated H.C. Wainwright Buy $19
Feb-28-19Downgrade Needham Buy → Hold
Aug-08-18Reiterated Needham Buy $15 → $14
Jul-16-18Upgrade Ladenburg Thalmann Neutral → Buy
Apr-04-18Initiated Leerink Partners Outperform $15
Mar-06-18Reiterated Needham Buy $5 → $15
Mar-06-18Downgrade Ladenburg Thalmann Buy → Neutral
Mar-05-18Reiterated BTIG Research Buy $8 → $13
Jun-21-17Initiated BTIG Research Buy $6
Mar-13-17Reiterated Needham Buy $9 → $6
Dec-22-16Initiated Piper Jaffray Overweight $6
Nov-09-16Reiterated Needham Buy $12 → $9
Apr-05-16Downgrade BofA/Merrill Buy → Neutral
Mar-11-16Upgrade Needham Hold → Buy $12
May-06-21 03:31AM  
May-05-21 08:35AM  
07:00AM  
06:45AM  
Apr-28-21 12:34PM  
Apr-23-21 10:36PM  
Apr-21-21 08:30AM  
Apr-09-21 09:24AM  
Mar-18-21 05:40PM  
08:16AM  
Mar-17-21 06:00PM  
Mar-10-21 05:50PM  
08:30AM  
Mar-08-21 07:43AM  
Mar-04-21 06:33AM  
Mar-02-21 08:30AM  
Feb-24-21 02:01PM  
08:50AM  
08:00AM  
06:30AM  
Feb-22-21 08:30AM  
Feb-16-21 08:30AM  
Feb-12-21 08:30AM  
Feb-10-21 08:00AM  
Feb-04-21 12:00PM  
Feb-01-21 09:42AM  
05:20AM  
Jan-25-21 08:30AM  
Jan-11-21 07:15AM  
Jan-08-21 08:30AM  
Jan-07-21 08:30AM  
07:05AM  
Jan-06-21 12:48PM  
Dec-19-20 10:10PM  
Dec-18-20 08:30AM  
Nov-09-20 11:44AM  
Nov-05-20 10:32PM  
08:00AM  
Nov-03-20 09:43AM  
05:54AM  
Nov-02-20 08:30AM  
06:40AM  
Oct-30-20 03:54PM  
Oct-29-20 11:30AM  
11:24AM  
Oct-22-20 08:30AM  
Oct-14-20 08:00AM  
Oct-12-20 10:35AM  
Oct-09-20 08:30AM  
Sep-16-20 07:30AM  
07:30AM  
Sep-09-20 08:30AM  
Sep-04-20 08:30AM  
Aug-25-20 08:25AM  
07:00AM  
Aug-10-20 09:19AM  
Aug-05-20 08:00AM  
Jul-22-20 08:30AM  
Jul-15-20 08:33AM  
Jul-09-20 08:30AM  
Jun-30-20 07:00AM  
07:00AM  
Jun-23-20 01:48PM  
May-28-20 03:38AM  
May-27-20 11:14AM  
May-26-20 09:27AM  
May-13-20 08:30AM  
May-06-20 12:02AM  
May-05-20 09:34AM  
08:00AM  
Apr-22-20 08:30AM  
Apr-10-20 09:00AM  
Apr-08-20 08:30AM  
Apr-02-20 02:58PM  
09:00AM  
Mar-31-20 09:39AM  
Mar-10-20 03:17AM  
Mar-04-20 08:29AM  
Mar-03-20 09:28AM  
Feb-25-20 08:00AM  
06:15AM  
Feb-24-20 10:04AM  
09:05AM  
09:02AM  
Feb-19-20 08:00AM  
Feb-14-20 09:49AM  
Feb-13-20 08:48AM  
08:44AM  
Feb-12-20 08:06AM  
07:38AM  
Feb-11-20 08:00AM  
Feb-10-20 10:20AM  
Jan-31-20 12:46PM  
Jan-09-20 08:00AM  
Jan-06-20 06:30AM  
Dec-19-19 07:07AM  
Dec-17-19 02:46PM  
Dec-11-19 09:48AM  
Dec-06-19 07:20AM  
Nov-06-19 10:55AM  
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Colangelo DominickPresident and CEOApr 19Option Exercise25.807,563195,125173,983Apr 20 04:15 PM
Colangelo DominickPresident and CEOApr 19Sale58.0140,0002,320,203142,973Apr 20 04:15 PM
Colangelo DominickPresident and CEOMar 30Option Exercise25.807,500193,500175,050Mar 30 04:50 PM
Hopper Jonathan MarkChief Medical OfficerMar 30Option Exercise10.9533,438366,14649,584Mar 31 04:17 PM
Hopper Jonathan MarkChief Medical OfficerMar 30Sale51.4017,924921,27022,966Mar 31 04:17 PM
Colangelo DominickPresident and CEOMar 29Sale51.0140,0002,040,254167,550Mar 30 04:50 PM
Rubino Alan LDirectorMar 19Option Exercise45.205,000226,0007,644Mar 22 04:19 PM
Colangelo DominickPresident and CEOMar 01Option Exercise3.8028,355107,696243,742Mar 02 04:15 PM
Colangelo DominickPresident and CEOMar 01Sale48.1140,0001,924,227207,550Mar 02 04:15 PM
Hopper Jonathan MarkChief Medical OfficerFeb 11Option Exercise0.001,625025,371Feb 12 04:17 PM
Colangelo DominickPresident and CEOFeb 11Option Exercise0.007,5000222,462Feb 12 04:16 PM
Halpin MichaelChief Operating OfficerFeb 11Option Exercise0.003,50006,953Feb 12 04:12 PM
Halpin MichaelChief Operating OfficerFeb 06Option Exercise0.001,87504,345Feb 08 04:26 PM
Hopper Jonathan MarkChief Medical OfficerFeb 06Option Exercise0.00650024,010Feb 08 04:25 PM
Colangelo DominickPresident and CEOFeb 06Option Exercise0.006,9380218,040Feb 08 04:24 PM
Halpin MichaelChief Operating OfficerDec 21Option Exercise2.6530,00079,50032,279Dec 23 04:10 PM
Hopper Jonathan MarkChief Medical OfficerDec 21Option Exercise10.9543,264473,74135,069Dec 23 04:11 PM
Hopper Jonathan MarkChief Medical OfficerDec 21Sale26.5424,235643,1594,331Dec 23 04:11 PM
Halpin MichaelChief Operating OfficerDec 21Sale26.2830,000788,4002,279Dec 23 04:10 PM
ZERBE ROBERT L MDDirectorNov 23Option Exercise3.2530,00097,50049,295Nov 24 04:09 PM
ZERBE ROBERT L MDDirectorNov 23Sale23.5517,500412,12531,795Nov 24 04:09 PM
Halpin MichaelChief Operating OfficerJun 23Option Exercise7.2014,751106,20716,373Jun 24 04:19 PM
Halpin MichaelChief Operating OfficerJun 23Sale15.0114,751221,4131,622Jun 24 04:19 PM
Halpin MichaelChief Operating OfficerJun 16Option Exercise2.652,8907,6585,624Jun 18 04:03 PM
Halpin MichaelChief Operating OfficerJun 16Sale15.004,00260,0301,622Jun 18 04:03 PM
Colangelo DominickPresident and CEOMay 08Option Exercise2.7513,12536,094210,492May 08 04:09 PM